ArticleInfection and drug resistance2020
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database.
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 68 citations in OpenAlex.
- Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial.Nature medicine · 2026Trial
- Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice.Frontiers in pharmacology · 2025Article
- Favipiravir-induced bradycardia: A case report.Clinical case reports · 2024Article
- Self-reported side effects of COVID-19 vaccines among health professions students in India.PeerJ · 2024Article
- What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.Virology journal · 2023Review
- Molecular Determinants, Clinical Manifestations and Effects of Immunization on Cardiovascular Health During COVID-19 Pandemic Era - A Review.Current problems in cardiology · 2023Review
- Telepharmacy during home isolation: drug-related problems and pharmaceutical care in COVID-19 patients receiving antiviral therapy in Thailand.Journal of pharmaceutical policy and practice · 2023Article
- Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study.Tropical medicine and infectious disease · 2023Article
- A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19.Vaccines · 2023Review
- Severity of COVID-19 in Patients with Diarrhoea: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2023Review
- A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19.Iranian journal of pharmaceutical research : IJPR · 2022Article
- Article
- Junctional bradycardia in a patient with COVID-19: A case report.World journal of clinical cases · 2022Article
- Safety profile of COVID-19 drugs in a real clinical setting.European journal of clinical pharmacology · 2022Review
- Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.Life (Basel, Switzerland) · 2022Review
- Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications.Journal of family medicine and primary care · 2022Article
- TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.Acta clinica Croatica · 2022Review
- Functional food: complementary to fight against COVID-19.Beni-Suef University journal of basic and applied sciences · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 caused by SARS-CoV-2 virus emerged as an unprecedented challenge to discover effective drugs for its prevention and cure. Hyperinflammation-induced lung damage is one of the poor prognostic indicators causing a higher rate of morbidity and mortality of COVID-19 patients. Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety. Thus, the present study was undertaken to evaluate the adverse drug events (ADEs) reported in the WHO pharmacovigilance database.
methodsThis study analyzed all suspected ADEs related to favipiravir reported from 2015. The reports were analyzed based on age, gender, and seriousness of ADEs at the System Organ Classification (SOC) level and the individual Preferred Term (PT) level.
resultsThis study is based on 194 ADEs reported from 93 patients. Most frequent ADEs suspected to be caused by the favipiravir included increased hepatic enzymes, nausea and vomiting, tachycardia, and diarrhea. Severe and fatal ADEs occurred more frequently in men and those over the age of 64 years. Blood and lymphatic disorders, cardiac disorders, hepatobiliary disorders, injury poisoning, and procedural complications were more common manifestations of severe ADEs.
conclusionThis study revealed that favipiravir appears to be a relatively safe drug. An undiscovered anti-inflammatory activity of favipiravir may explain the improvement in critically ill patients and reduce inflammatory markers. Currently, the data is based on very few patients. A more detailed assessment of the uncommon ADEs needs to be analyzed when more information will be available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.